Johnson & Johnson’s TREMFYA Achieves 28.3% Remission Rate in Phase 3 FUZION
Johnson & Johnson’s Phase 3 FUZION study showed TREMFYA achieved combined fistula remission in 28.3% on 100 mg q8w and 27.0% on 200 mg q4w, versus 10.3% placebo. This is first in 20 years showing IL-23 inhibitor efficacy in perianal fistulizing Crohn’s disease, supporting label expansion for TREMFYA.
1. Phase 3 FUZION Study Design
FUZION is a randomized, placebo-controlled, double-blind, multicenter Phase 3 trial evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. Patients were randomized 2:2:1 to receive TREMFYA 100 mg subcutaneously every eight weeks, 200 mg every four weeks, or placebo, with MRI-confirmed active draining fistulas at baseline.
2. Efficacy Results
At Week 24, combined fistula remission—defined as complete external closure of draining fistulas with no MRI fluid collections—was achieved by 28.3% of patients on 100 mg q8w and 27.0% on 200 mg q4w, versus 10.3% for placebo. Both dosing regimens showed statistically significant treatment differences (p=0.007 and p=0.013).
3. Safety Profile
Adverse events through 24 weeks were consistent with TREMFYA’s established safety profile in Crohn’s disease, with no new safety signals observed. The tolerability across dosing regimens aligns with previous Phase 2b DUET studies in inflammatory bowel disease.
4. Market Implications and Next Steps
This first positive randomized trial in two decades for perianal fistulizing Crohn’s disease positions TREMFYA for potential label expansion in a segment affecting up to 25% of Crohn’s patients. Enrollment has begun in the head-to-head CHARGE study comparing TREMFYA with risankizumab.